Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Cash & Equivalents (2016 - 2026)

Nutex Health (NUTX) has disclosed Cash & Equivalents for 17 consecutive years, with $207.3 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 144.72% year-over-year to $207.3 million; the TTM value through Mar 2026 reached $207.3 million, up 144.72%, while the annual FY2025 figure was $185.6 million, 356.63% up from the prior year.
  • Cash & Equivalents hit $207.3 million in Q1 2026 for Nutex Health, up from $185.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $207.3 million in Q1 2026 and bottomed at $3.3 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $66.8 million, with a median of $40.6 million recorded in 2024.
  • On a YoY basis, Cash & Equivalents climbed as much as 909.53% in 2023 and fell as far as 35.77% in 2023.
  • Nutex Health's Cash & Equivalents stood at $34.3 million in 2022, then tumbled by 35.77% to $22.0 million in 2023, then soared by 84.71% to $40.6 million in 2024, then soared by 356.63% to $185.6 million in 2025, then increased by 11.73% to $207.3 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $207.3 million, $185.6 million, and $166.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.